HK1067039A1 - A combination comprising combretastatin and anticancer agents - Google Patents
A combination comprising combretastatin and anticancer agentsInfo
- Publication number
- HK1067039A1 HK1067039A1 HK04109982A HK04109982A HK1067039A1 HK 1067039 A1 HK1067039 A1 HK 1067039A1 HK 04109982 A HK04109982 A HK 04109982A HK 04109982 A HK04109982 A HK 04109982A HK 1067039 A1 HK1067039 A1 HK 1067039A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- combretastatin
- combination
- anticancer agents
- anticancer
- agents
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27562701P | 2001-03-15 | 2001-03-15 | |
PCT/EP2002/006758 WO2004037258A1 (en) | 2001-03-15 | 2002-03-15 | A combination comprising combretastatin and anticancer agents |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1067039A1 true HK1067039A1 (en) | 2005-04-01 |
Family
ID=23053164
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK04109982A HK1067039A1 (en) | 2001-03-15 | 2004-12-16 | A combination comprising combretastatin and anticancer agents |
Country Status (38)
Country | Link |
---|---|
US (4) | US20020183266A1 (sh) |
EP (1) | EP1439839B8 (sh) |
JP (1) | JP4991107B2 (sh) |
KR (1) | KR100849610B1 (sh) |
CN (2) | CN1935134B (sh) |
AR (1) | AR032989A1 (sh) |
AT (1) | ATE433750T1 (sh) |
AU (1) | AU2002304574B2 (sh) |
BR (1) | BR0208017A (sh) |
CA (2) | CA2673449C (sh) |
CY (1) | CY1109364T1 (sh) |
CZ (1) | CZ302451B6 (sh) |
DE (1) | DE60232673D1 (sh) |
DK (1) | DK1439839T3 (sh) |
EA (1) | EA006316B1 (sh) |
EC (1) | ECSP034766A (sh) |
ES (1) | ES2327617T3 (sh) |
HK (1) | HK1067039A1 (sh) |
HR (1) | HRPK20030734B3 (sh) |
HU (1) | HU228510B1 (sh) |
IL (2) | IL157891A0 (sh) |
MA (1) | MA27000A1 (sh) |
ME (2) | ME00056B (sh) |
MX (1) | MXPA03007552A (sh) |
NO (1) | NO332661B1 (sh) |
NZ (1) | NZ527526A (sh) |
PE (1) | PE20020909A1 (sh) |
PL (1) | PL205728B1 (sh) |
PT (1) | PT1439839E (sh) |
RS (1) | RS50682B (sh) |
SI (1) | SI1439839T1 (sh) |
SK (1) | SK287908B6 (sh) |
TN (1) | TNSN03060A1 (sh) |
TW (1) | TWI306028B (sh) |
UA (1) | UA75127C2 (sh) |
UY (1) | UY27208A1 (sh) |
WO (2) | WO2004037258A1 (sh) |
ZA (1) | ZA200306789B (sh) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUP0102521A3 (en) | 1998-04-03 | 2003-08-28 | Ajinomoto Kk | Antitumor agents comprising a stilbene derivative and a platinum coordination compound |
US20050209310A1 (en) * | 2000-12-22 | 2005-09-22 | Chaplin David J | Methods for modulating tumor growth and metastasis |
GB0410817D0 (en) * | 2004-05-14 | 2004-06-16 | Angiogene Pharm Ltd | Vascular damaging therapy |
CN100431606C (zh) * | 2004-11-22 | 2008-11-12 | 山东蓝金生物工程有限公司 | 一种抗癌药物组合物 |
CN1319978C (zh) * | 2005-04-06 | 2007-06-06 | 西南合成制药股份有限公司 | 康布瑞汀化合物的制备方法 |
FR2895258B1 (fr) * | 2005-12-22 | 2008-03-21 | Aventis Pharma Sa | Combinaison comprenant de la combretastatine et des agents anticancereux |
US20080104512A1 (en) * | 2006-10-31 | 2008-05-01 | Motorola, Inc. | Method and apparatus for providing realtime feedback in a voice dialog system |
AU2008326251B2 (en) * | 2007-11-21 | 2014-03-06 | Mateon Therapeutics, Inc. | Method for treating hematopoietic neoplasms |
US20090209496A1 (en) * | 2008-02-15 | 2009-08-20 | David Chaplin | Methods and compositions for enhancing the efficacy of rtk inhibitors |
FR2939665B1 (fr) * | 2008-12-12 | 2011-10-07 | Sanofi Aventis | Combinaison antitumorale associant l'ave8062a et le docetaxel |
FR2945210B1 (fr) * | 2009-05-07 | 2011-07-01 | Sanofi Aventis | Combinaison antitumorale comprenant l'ave8062 et le sorafenib |
EP2481404A1 (en) | 2010-11-15 | 2012-08-01 | Sanofi | An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative |
EP2397135A1 (en) | 2010-06-18 | 2011-12-21 | Sanofi | An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative |
CA2802974A1 (en) | 2010-06-18 | 2011-12-22 | Sanofi | An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative |
EP2407161A1 (en) | 2010-07-13 | 2012-01-18 | Sanofi | An antitumoral combination comprising ombrabulin and bevacizumab |
FR2968557A1 (fr) | 2010-12-09 | 2012-06-15 | Sanofi Aventis | Combinaison antitumorale comprenant un derive de la famille des combretastatines et le cetuximab |
FR2978663A1 (fr) | 2011-08-01 | 2013-02-08 | Sanofi Sa | Combinaison antitumorale comprenant l'ombrabuline et le cetuximab, associee a la radiotherapie |
FR2978662A1 (fr) | 2011-08-01 | 2013-02-08 | Sanofi Sa | Combinaison antitumorale comprenant l'ombrabuline et le cisplatine, associee a la radiotherapie |
US11419934B2 (en) | 2015-08-18 | 2022-08-23 | Oncotelic Therapeutics, Inc. | Use of VDAS to enhance immunomodulating therapies against tumors |
US9980953B2 (en) * | 2016-09-26 | 2018-05-29 | Chong Kun Dang Pharmaceutical Corp. | Combined composition for preventing or treating cancer comprising a benzophenone thiazole derivatives as a VDA and topoisomerase inhibitor |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2601675B1 (fr) | 1986-07-17 | 1988-09-23 | Rhone Poulenc Sante | Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent |
FR2601676B1 (fr) * | 1986-07-17 | 1988-09-23 | Rhone Poulenc Sante | Procede de preparation du taxol et du desacetyl-10 taxol |
US4996237A (en) * | 1987-01-06 | 1991-02-26 | Arizona Board Of Regents | Combretastatin A-4 |
MX9102128A (es) | 1990-11-23 | 1992-07-08 | Rhone Poulenc Rorer Sa | Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene |
US5430062A (en) * | 1992-05-21 | 1995-07-04 | Research Corporation Technologies, Inc. | Stilbene derivatives as anticancer agents |
US5731353A (en) * | 1993-09-08 | 1998-03-24 | Ajinomoto Co., Inc. | Stilbene derivatives and pharmaceutical compositions containing them |
TW325458B (en) * | 1993-09-08 | 1998-01-21 | Ajinomoto Kk | Stilbene derivatives and pharmaceutical compositions comprising the same for anti-cancer |
US5561122A (en) * | 1994-12-22 | 1996-10-01 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Combretastatin A-4 prodrug |
TW334418B (en) * | 1995-03-07 | 1998-06-21 | Ajinomoto Kk | Stilbene derivatives and pharmaceutical compositions |
HUP0102521A3 (en) * | 1998-04-03 | 2003-08-28 | Ajinomoto Kk | Antitumor agents comprising a stilbene derivative and a platinum coordination compound |
US6242770B1 (en) * | 1998-08-31 | 2001-06-05 | Gary Bela Bronner | Diode connected to a magnetic tunnel junction and self aligned with a metallic conductor and method for forming the same |
GB9903404D0 (en) * | 1999-02-16 | 1999-04-07 | Angiogene Pharm Ltd | Methods of treatment and compositions useful for the treatment of diseases involving angiogenesis |
JP2002541200A (ja) * | 1999-04-14 | 2002-12-03 | デイナ−ファーバー キャンサー インスティチュート,インコーポレイテッド | 癌の処置のための方法および組成物 |
US6465448B1 (en) * | 1999-08-13 | 2002-10-15 | Case Western Reserve University | Methoxyamine potentiation of temozolomide anti-cancer activity |
US6448030B1 (en) * | 2000-02-18 | 2002-09-10 | University Of Nevada-Las Vegas | Method for predicting the efficacy of anti-cancer drugs |
MXPA03002882A (es) * | 2000-10-27 | 2004-12-03 | Aventis Pharma Sa | Una combinacion que contiene camptotecina y un derivado de estilbeno para el tratamiento del cancer. |
JP2004523517A (ja) * | 2000-12-22 | 2004-08-05 | ブリストル−マイヤーズ スクイブ カンパニー | 腫瘍増殖および転移を調節するための方法 |
US6466448B1 (en) * | 2001-06-11 | 2002-10-15 | Network Appliance, Inc. | Riser board retaining and air ducting structure for printed circuit boards |
-
2002
- 2002-03-08 US US10/092,508 patent/US20020183266A1/en not_active Abandoned
- 2002-03-14 AR ARP020100914A patent/AR032989A1/es unknown
- 2002-03-14 UY UY27208A patent/UY27208A1/es not_active Application Discontinuation
- 2002-03-15 MX MXPA03007552A patent/MXPA03007552A/es active IP Right Grant
- 2002-03-15 WO PCT/EP2002/006758 patent/WO2004037258A1/en active IP Right Grant
- 2002-03-15 NO NO20034022A patent/NO332661B1/no not_active IP Right Cessation
- 2002-03-15 IL IL15789102A patent/IL157891A0/xx unknown
- 2002-03-15 CN CN2006101388753A patent/CN1935134B/zh not_active Expired - Fee Related
- 2002-03-15 US US10/097,926 patent/US6933320B2/en not_active Expired - Fee Related
- 2002-03-15 CA CA2673449A patent/CA2673449C/en not_active Expired - Fee Related
- 2002-03-15 SK SK1155-2003A patent/SK287908B6/sk not_active IP Right Cessation
- 2002-03-15 HU HU0600233A patent/HU228510B1/hu not_active IP Right Cessation
- 2002-03-15 SI SI200230915T patent/SI1439839T1/sl unknown
- 2002-03-15 PL PL374406A patent/PL205728B1/pl not_active IP Right Cessation
- 2002-03-15 KR KR1020037012033A patent/KR100849610B1/ko not_active IP Right Cessation
- 2002-03-15 NZ NZ527526A patent/NZ527526A/en not_active IP Right Cessation
- 2002-03-15 TW TW091104922A patent/TWI306028B/zh not_active IP Right Cessation
- 2002-03-15 WO PCT/EP2002/003322 patent/WO2002074229A2/en not_active Application Discontinuation
- 2002-03-15 ME MEP-2008-162A patent/ME00056B/me unknown
- 2002-03-15 ES ES02732758T patent/ES2327617T3/es not_active Expired - Lifetime
- 2002-03-15 PT PT02732758T patent/PT1439839E/pt unknown
- 2002-03-15 RS YUP-713/03A patent/RS50682B/sr unknown
- 2002-03-15 EA EA200301015A patent/EA006316B1/ru not_active IP Right Cessation
- 2002-03-15 JP JP2004545736A patent/JP4991107B2/ja not_active Expired - Fee Related
- 2002-03-15 CA CA002470484A patent/CA2470484C/en not_active Expired - Fee Related
- 2002-03-15 CZ CZ20032476A patent/CZ302451B6/cs not_active IP Right Cessation
- 2002-03-15 EP EP02732758A patent/EP1439839B8/en not_active Expired - Lifetime
- 2002-03-15 DE DE60232673T patent/DE60232673D1/de not_active Expired - Lifetime
- 2002-03-15 AT AT02732758T patent/ATE433750T1/de active
- 2002-03-15 AU AU2002304574A patent/AU2002304574B2/en not_active Ceased
- 2002-03-15 UA UA2003109292A patent/UA75127C2/uk unknown
- 2002-03-15 ME MEP-162/08A patent/MEP16208A/xx unknown
- 2002-03-15 BR BR0208017-6A patent/BR0208017A/pt not_active IP Right Cessation
- 2002-03-15 DK DK02732758T patent/DK1439839T3/da active
- 2002-03-15 CN CNB028065832A patent/CN1290504C/zh not_active Expired - Fee Related
- 2002-03-15 PE PE2002000204A patent/PE20020909A1/es not_active Application Discontinuation
-
2003
- 2003-07-08 TN TNPCT/EP2002/003322A patent/TNSN03060A1/en unknown
- 2003-08-29 ZA ZA2003/06789A patent/ZA200306789B/en unknown
- 2003-09-09 MA MA27301A patent/MA27000A1/fr unknown
- 2003-09-11 IL IL157891A patent/IL157891A/en not_active IP Right Cessation
- 2003-09-12 HR HR20030734A patent/HRPK20030734B3/xx not_active IP Right Cessation
- 2003-09-12 EC EC2003004766A patent/ECSP034766A/es unknown
-
2004
- 2004-11-23 US US10/995,998 patent/US20050075295A1/en not_active Abandoned
- 2004-12-16 HK HK04109982A patent/HK1067039A1/xx not_active IP Right Cessation
-
2007
- 2007-02-21 US US11/677,178 patent/US20070149476A1/en not_active Abandoned
-
2009
- 2009-09-16 CY CY20091100954T patent/CY1109364T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1067039A1 (en) | A combination comprising combretastatin and anticancer agents | |
IL193618A0 (en) | Thrombopoietin mimetics | |
EP1349613A4 (en) | THROMBOPOIETINMIMETIKA | |
GB0009605D0 (en) | Medicaments | |
EP1250357A4 (en) | MYOSTATIN AND ITS MIMETIC | |
GB0002312D0 (en) | Medicaments | |
EP1511753A4 (en) | ANTIMICROBIAL MEDIUM AND ITS USE | |
PL366218A1 (en) | Phenyl-substituted 2-enamino-keto nitriles | |
GB0015324D0 (en) | Medicaments | |
AU2002302465A1 (en) | A combination comprising combretastatin and anticancer agents | |
EP1386919A4 (en) | REMEDIES | |
SI1369122T1 (sl) | Protirakavo sredstvo | |
GB2358076B (en) | Speaking numbers | |
AU147037S (en) | A flag | |
AU145101S (en) | A flag | |
AU145252S (en) | A flag | |
AU147985S (en) | A flag | |
AU141411S (en) | Pinata/party novelty | |
AU141408S (en) | Pinata/party novelty | |
AU141410S (en) | Pinata/party novelty | |
AU141409S (en) | Pinata/party novelty | |
GB0026786D0 (en) | Delivery devices | |
GB0027583D0 (en) | Delivery devices | |
GB0020172D0 (en) | Delivery devices | |
GB0015851D0 (en) | Medicaments |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20140315 |